More articles from Update on Acute Coronary Syndromes
- ‘Rescue’ angioplasty for failed thrombolysis
Although data are few, a strategy of angioplasty-after-thrombolysis seems reasonable and beneficial.
- Angioplasty and stenting in acute coronary syndromes: Who, when, how, and why
Questions remain about when and how to use these interventions.
- Glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes
These potent antiplatelet agents constitute a breakthrough, hut questions remain about their safety, cost-effectiveness, and proper empiric use. With an illustration explaining the paradoxical prothrombotic effect of fibrinolytic drugs.
- Third in a Series
Most patients with acute coronary syndromes arc candidates for heparin therapy. Low-molecular-weight heparin may offer advantages over standard, unfractionated heparin.
- Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: Underused treatments could save thousands of lives
Aspirin is the cornerstone of therapy for unstable angina and acute myocardial infarction. Yet, in spite of clear data, it is often not given or given late. An accompanying illustration shows how antiplatelet drugs block the cascade of platelet aggregation.
- Drug Therapy, Medical Management, and Interventional Strategies
In this issue, we begin a series designed to guide the clinician through the bewildering array of treatment options.
- The pathogenesis and spectrum of acute coronary syndromes: From plaque formation to thrombosis
Acute coronary syndromes occur when vulnerable plaque ruptures, leading to acute thrombosis. With an illustration explaining this chain of events.